Century Therapeutics (IPSC)
(Delayed Data from NSDQ)
$0.54 USD
-0.02 (-2.80%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $0.54 0.00 (-0.44%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IPSC 0.54 -0.02(-2.80%)
Will IPSC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPSC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPSC
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock
IPSC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Other News for IPSC
Century Therapeutics files $200M mixed shelf offering
Century Therapeutics (IPSC) Files for $200M Mixed Securities Offering | IPSC Stock News
Century Therapeutics files $200M mixed securities shelf
Century Therapeutics Holds 2025 Annual Stockholders Meeting
Leerink Partners Keeps Their Buy Rating on Century Therapeutics (IPSC)